Vascular endothelial mineralocorticoid receptors and epithelial sodium channels in metabolic syndrome and related cardiovascular disease.
endothelial cells
epithelial sodium channels
metabolic syndrome
mineralocorticoid receptors
Journal
Journal of molecular endocrinology
ISSN: 1479-6813
Titre abrégé: J Mol Endocrinol
Pays: England
ID NLM: 8902617
Informations de publication
Date de publication:
01 10 2023
01 10 2023
Historique:
received:
03
05
2023
accepted:
22
08
2023
medline:
14
9
2023
pubmed:
23
8
2023
entrez:
23
8
2023
Statut:
epublish
Résumé
Metabolic syndrome is a group of risk factors that increase the risk of developing metabolic and cardiovascular disease (CVD) and include obesity, dyslipidemia, insulin resistance, atherosclerosis, hypertension, coronary artery disease, and heart failure. Recent research indicates that excessive production of aldosterone and associated activation of mineralocorticoid receptors (MR) impair insulin metabolic signaling, promote insulin resistance, and increase the risk of developing metabolic syndrome and CVD. Moreover, activation of specific epithelial sodium channels (ENaC) in endothelial cells (EnNaC), which are downstream targets of endothelial-specific MR (ECMR) signaling, are also believed to play a crucial role in the development of metabolic syndrome and CVD. These adverse effects of ECMR/EnNaC activation are mediated by increased oxidative stress, inflammation, and lipid metabolic disorders. It is worth noting that ECMR/EnNaC activation and the pathophysiology underlying metabolic syndrome and CVD appears to exhibit sexual dimorphism. Targeting ECMR/EnNaC signaling may have a beneficial effect in preventing insulin resistance, diabetes, metabolic syndrome, and related CVD. This review aims to examine our current understanding of the relationship between MR activation and increased metabolic syndrome and CVD, with particular emphasis placed on the role for endothelial-specific ECMR/EnNaC signaling in these pathological processes.
Identifiants
pubmed: 37610001
doi: 10.1530/JME-23-0066
pii: JME-23-0066
pmc: PMC10502958
doi:
pii:
Substances chimiques
Receptors, Mineralocorticoid
0
Epithelial Sodium Channels
0
Types de publication
Review
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NIDDK NIH HHS
ID : R01 DK124329
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL073101
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL107910
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL085119
Pays : United States
Références
Circulation. 2015 Dec 1;132(22):2134-45
pubmed: 26362633
J Atheroscler Thromb. 2022 Jun 1;29(6):937-952
pubmed: 34305082
Front Physiol. 2017 Jun 30;8:456
pubmed: 28713285
Hypertension. 2015 Jul;66(1):99-107
pubmed: 26015449
Nephrol Dial Transplant. 2016 Feb;31(2):200-5
pubmed: 26163195
Cureus. 2021 Feb 21;13(2):e13471
pubmed: 33777560
Biochim Biophys Acta Mol Basis Dis. 2021 Jan 1;1867(1):165989
pubmed: 33065235
Cardiovasc Diabetol. 2013 Nov 21;12:172
pubmed: 24261558
Endocrinology. 2016 Oct;157(10):3844-3855
pubmed: 27526033
Am J Hypertens. 2016 Apr;29(4):415-23
pubmed: 26927805
J Am Heart Assoc. 2013 Feb 22;2(1):e000018
pubmed: 23525413
Curr Hypertens Rep. 2018 Feb 26;20(2):12
pubmed: 29480368
J Pharmacol Exp Ther. 2015 Apr;353(1):27-34
pubmed: 25617244
Eur Heart J. 2022 Aug 14;43(31):2931-2945
pubmed: 35713973
J Am Heart Assoc. 2018 Feb 16;7(4):
pubmed: 29453308
Biomolecules. 2018 Sep 18;8(3):
pubmed: 30231508
Int J Cardiol. 2017 Apr 1;232:233-242
pubmed: 28089144
Metabolism. 2020 Aug;109:154223
pubmed: 32275972
Metabolism. 2018 Jan;78:69-79
pubmed: 28920862
Hypertension. 2012 May;59(5):1069-78
pubmed: 22493070
J Am Heart Assoc. 2015 Oct 12;4(10):e002137
pubmed: 26459931
Hypertension. 2018 Jan;71(1):15-21
pubmed: 29133358
Hypertension. 1995 Jan;25(1):30-6
pubmed: 7843750
Hypertension. 2004 May;43(5):957-62
pubmed: 15007028
Circ Res. 2008 Jun 6;102(11):1359-67
pubmed: 18467630
Cell Rep. 2017 Oct 24;21(4):1009-1020
pubmed: 29069584
Diabetes. 2015 Jan;64(1):236-42
pubmed: 25125488
Am J Physiol Regul Integr Comp Physiol. 2014 Nov 15;307(10):R1198-206
pubmed: 25253086
Endocrinology. 2019 Dec 1;160(12):2918-2928
pubmed: 31617909
Circ Res. 2016 Mar 18;118(6):935-943
pubmed: 26879229
J Biol Chem. 2002 Sep 13;277(37):33541-4
pubmed: 12167633
Metabolism. 2022 May;130:155165
pubmed: 35183546
Medicine (Baltimore). 2018 Apr;97(16):e0500
pubmed: 29668634
J Endocrinol. 2022 Apr 15;253(3):R65-R76
pubmed: 35266453
Endocrinology. 2014 Nov;155(11):4296-304
pubmed: 25167221
PLoS One. 2019 May 29;14(5):e0217546
pubmed: 31141569
Am J Physiol Cell Physiol. 2023 Jan 1;324(1):C193-C204
pubmed: 36440858
J Clin Endocrinol Metab. 2007 Jul;92(7):2552-8
pubmed: 17488800
Diabetes. 2021 Feb;70(2):577-588
pubmed: 33262120
Biol Sex Differ. 2019 May 9;10(1):24
pubmed: 31072402
Endocrinology. 2022 Oct 11;163(11):
pubmed: 36039677
Am J Physiol Regul Integr Comp Physiol. 2022 Mar 1;322(3):R253-R262
pubmed: 35107025
Am J Physiol Regul Integr Comp Physiol. 2021 Mar 1;320(3):R276-R286
pubmed: 33438511
Drugs. 2015 Apr;75(5):473-85
pubmed: 25787734
Acta Physiol (Oxf). 2022 Feb;234(2):e13731
pubmed: 34519423
Circulation. 2005 Sep 20;112(12):1719-27
pubmed: 16157770
Front Endocrinol (Lausanne). 2020 Apr 21;11:223
pubmed: 32373073
FASEB J. 2020 Sep;34(9):12450-12465
pubmed: 32729974
Circulation. 1995 Mar 1;91(5):1432-43
pubmed: 7867184
Arterioscler Thromb Vasc Biol. 2019 Aug;39(8):1588-1601
pubmed: 31294624
Endocrinology. 2010 May;151(5):2040-9
pubmed: 20211973
Hypertension. 2019 Apr;73(4):849-858
pubmed: 30827147
Hypertension. 2015 Dec;66(6):1159-1167
pubmed: 26441470
Circ Res. 2005 Apr 1;96(6):643-50
pubmed: 15718497
J Am Coll Cardiol. 2005 Apr 19;45(8):1243-8
pubmed: 15837256
Am J Physiol Renal Physiol. 2016 May 1;310(9):F812-20
pubmed: 26841823
Hypertension. 2018 Sep;72(3):731-738
pubmed: 29987101
Hypertension. 2020 Jul;76(1):113-120
pubmed: 32418495
J Endocrinol. 2017 Jul;234(1):T67-T82
pubmed: 28634267
J Clin Endocrinol Metab. 2006 Sep;91(9):3457-63
pubmed: 16822818